Wednesday 14 May 2014

Monoclonal Antibody Shows Promise in Childhood Brain Tumor


Tumors shrank or disappeared in some patients with advanced neuroblastoma in a Phase 1 study of an immune therapy manufactured at St. Jude Children's Research Hospital.
Tumors shrank or disappeared and disease progression 
Monoclonal Antibody Shows Promise in Childhood Brain Tumor




ANTHONY MELVIN CRASTO
THANKS AND REGARD'S
DR ANTHONY MELVIN CRASTO Ph.D
amcrasto@gmail.com
MOBILE-+91 9323115463
GLENMARK SCIENTIST ,  INDIA
web link
http://anthonycrasto.jimdo.com/
Congratulations! Your presentation titled "Anthony Crasto Glenmark scientist, helping millions with websites" has just crossed MILLION views.
アンソニー     安东尼   Энтони    안토니     أنتوني
join my process development group on google
you can post articles and will be administered by me on the google group which is very popular across the world
LinkedIn group
 
blogs are
 
shark

 

Tuesday 13 May 2014

MANAGEMENT SOLUTIONS GROUP LatAm - Gestión de Organizaciones de Salud, Farma & Biotech: PHARMA DEALS DURING MARCH 2014Following on from l...

MANAGEMENT SOLUTIONS GROUP LatAm - Gestión de Organizaciones de Salud, Farma & Biotech: PHARMA DEALS DURING MARCH 2014
Following on from l...
: PHARMA DEALS DURING MARCH 2014 Following on from  last month's Deal Watch , which included four transactions of over $1bn, Marc...

MANAGEMENT SOLUTIONS GROUP LatAm - Gestión de Organizaciones de Salud, Farma & Biotech: BIOTECH IPOs: WHAT ENTREPRENEURS CAN LEARN FROM A ...

MANAGEMENT SOLUTIONS GROUP LatAm - Gestión de Organizaciones de Salud, Farma & Biotech: BIOTECH IPOs: WHAT ENTREPRENEURS CAN LEARN FROM A ...: BIOTECH IPOs: WHAT ENTREPRENEURS CAN LEARN FROM A BANNER YEAR (Part 1 out of 2) The data is in, and there is no question that 2013...

MANAGEMENT SOLUTIONS GROUP LatAm - Gestión de Organizaciones de Salud, Farma & Biotech: BIOSIMILARS MARKET IS NOT EQUIVALENT TO GENERICS M...

MANAGEMENT SOLUTIONS GROUP LatAm - Gestión de Organizaciones de Salud, Farma & Biotech: BIOSIMILARS MARKET IS NOT EQUIVALENT TO GENERICS M...: BIOSIMILARS MARKET IS NOT EQUIVALENT TO GENERICS MARKET by Ben Comer For years now, the increased spend on healthcare in the U.S....